In last trading session, Moderna Inc (NASDAQ:MRNA) saw 14.76 million shares changing hands with its beta currently measuring 1.83. Company’s recent per share price level of $23.65 trading at -$0.37 or -1.54% at ring of the bell on the day assigns it a market valuation of $9.15B. That closing price of MRNA’s stock is at a discount of -620.8% from its 52-week high price of $170.47 and is indicating a premium of 2.11% from its 52-week low price of $23.15.

For Moderna Inc (MRNA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.83. Splitting up the data highlights that, out of 17 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 12 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -2.98 in the current quarter.

Moderna Inc (NASDAQ:MRNA) trade information

Upright in the red during last session for losing -1.54%, in the last five days MRNA remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $23.65 price level, adding 9.66% to its value on the day. Moderna Inc’s shares saw a change of -43.12% in year-to-date performance and have moved -2.99% in past 5-day. Moderna Inc (NASDAQ:MRNA) showed a performance of -9.87% in past 30-days.

Wall Street analysts have assigned a consensus price target of 54 to the stock, which implies a rise of 56.2% to its current value. Analysts have been projecting 45 as a low price target for the stock while placing it at a high target of 69. It follows that stock’s current price would drop -90.27% in reaching the projected high whereas dropping to the targeted low would mean a loss of -90.27% for stock’s current value.

Moderna Inc (MRNA) estimates and forecasts

This year revenue growth is estimated to fall -35.83% from the last financial year’s standing.

13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 110.85M for the same. And 13 analysts are in estimates of company making revenue of 1.15B in the next quarter. Company posted 241M and 1.86B of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -42.94% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -9.43% while estimates for its earnings growth in next 5 years are of 20.24%.

Moderna Inc (NASDAQ:MRNA)’s Major holders

BAILLIE GIFFORD & CO is the top institutional holder at MRNA for having 43.45 million shares of worth $5.16 billion. And as of 2024-06-30, it was holding 11.3149 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 39.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.3028 of outstanding shares, having a total worth of $4.7 billion.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 10.87 shares of worth $257.05 million or 2.81% of the total outstanding shares. The later fund manager was in possession of 9.17 shares on Dec 31, 2024, making its stake of worth around $216.76 million in the company or a holder of 2.37% of company’s stock.